ResAppDx revenue has just started, if they are "gas" out then time for new management. No spin, the technology hasn't changed since you've invested in RAP many years ago. Their core products are still acute respiratory diagnosis and chronic respiratory management.
Pfizer have dangled peanuts, some RAP shareholders short sighted monkeys., page-22
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)